[ad_1]
The ICDM (International Conference on Diabetes and Metabolic Diseases) is an international conference organized by the Korean Diabetes Association, celebrating its 10th anniversary, and held online to prevent the spread of a new coronavirus infection (Corona 19).
According to the company, inavogliflozin showed a statistically significant decrease in the amount of change in glycated hemoglobin (HbA1c) compared to placebo from the fourth week of administration when taken for 12 weeks in type 2 diabetes patients with poor control of the blood sugar At week 12, it decreased about 0.9% compared to placebo.
This is a statistically significant result, an additional reduction in glycated hemoglobin of about 0.2 to 0.3% compared to other SGLT2 inhibitors that have been done for Westerners, and more research is awaited.
At 12 weeks, when each subject’s treatment effect was assessed, the proportion of patients with glycated hemoglobin that reached 7.0% or less peaked at 61%, resulting in a 20% increase in the proportion of patients who were more effective than conventional SGLT-2 inhibitors. ), the proportion of patients whose glycated hemoglobin decreased by more than 0.5% was up to 72%, showing an excellent blood sugar lowering effect.
Furthermore, it was confirmed that only 2% of the side effects that can occur due to the mechanism of the SGLT-2 family of inhibitors, such as genital infection and urinary tract infection, are of excellent safety. This is a rating that is significantly lower than other SGLT-2 inhibitors showing 5-10% side effects.
Professor Park Kyung-soo, a professor of internal medicine at Seoul National University Hospital, who is the clinical trial coordinator for this study, said: “In a clinical study that compared navogliflozin with 200 Koreans for 12 weeks o more, compared to placebo, we confirm the excellent hypoglycemic effect and safety. “If the excellent hypoglycemic effect and good safety of Inabogliflozin are confirmed in various combination therapies, including single therapy, it is expected to be a good treatment option for patients with type 2 diabetes “.
Seung-ho Jeon, President of Daewoong Pharmaceutical, said: “As the excellent efficacy and safety of ‘Inabogliflozin’ has been demonstrated through the results of this phase 2 clinical trial, we will take further steps to create the best new drug ( best-in-class) of the SGLT-2 inhibitor family. “We will accelerate R&D for the global market through a wide range of overseas partnerships in the future.”
Meanwhile, ‘Inabogliflozin’, a treatment for type 2 diabetes, has completed phase 2 clinical trials in Korea and plans to conduct a phase 3 clinical trial to obtain indications for the treatment of type 2 diabetes during this year. Its goal is to be launched in Korea in 2023.
As SGLT-2 inhibitor drugs are expanding into drugs for heart failure and chronic kidney failure, inabogliflozin is expected to expand various indications, including obesity, heart and kidneys, as well as treatments for diabetes . The global market for diabetes treatment in major countries is expected to grow from 17 trillion won in 2019 to approximately 20 trillion won in 2024.
<© 2020 메디파나뉴스, 무단 전재 및 배포금지>‘The hub of Korean medical news’ Medipana News
